Milestone Scientific Inc. reports developments tied to computerized drug delivery instruments for dental and medical applications. The company’s Dynamic Pressure Sensing technology supports pressure-guided injection and fluid-aspiration procedures, including dental anesthesia delivery through The Wand STA system and medical applications such as CompuFlo for controlled epidural injections.
Recurring news themes include financial results, business-update calls, commercialization programs, physician and dental-practice adoption, distributor and reimbursement infrastructure, international product registrations, disposable utilization, operating expense initiatives, and capital actions involving common stock and warrants.
Milestone Scientific (MLSS) reported third-quarter revenue of $2,219,747, down year over year as lower dental sales outweighed medical growth. Medical segment revenue grew 136%. Gross margin rose to 72.3% from 69.5%, while operating expenses fell 15.3%. Net loss narrowed to $747,545 from $1,153,959.
Nine-month revenue increased 4.4% to $7,222,818, and net loss narrowed to $2,467,985 from $4,631,655. Cash totaled $1,315,401 at September 30. Director loans were eliminated through a debt-to-equity conversion.
Management reaffirmed 2026 revenue guidance of $9.8 million to $10.2 million and expects to approach or achieve profitability in the fourth quarter. Identified initiatives are expected to produce approximately $400,000 in additional annual savings. CompuFlo entered clinical use at Rothman Orthopaedics; a 79-patient study associated its use with approximately 91% lower adjusted odds of composite complications during spinal cord stimulator implantation.
Milestone Scientific (NYSE: MLSS) will host its third-quarter financial results conference call on November 13, 2026, at 8:30 AM Eastern Time. The call will cover the quarter ended September 30, 2026, corporate progress and other developments. The corrected call date is Friday, November 13, rather than Wednesday as previously stated.
Milestone Scientific (MLSS) reported medical segment revenue growth of more than 200% year over year as it expanded CompuFlo commercialization. The revenue comparison covers the second quarter of 2026. Its U.S. pipeline exceeds 500 commercial leads, with prospective healthcare-network opportunities at varying stages. Red One Medical provides access to federal healthcare customers, while distribution relationships support expansion in Italy, Qatar and Chile.
The company illustrated $33 million in potential annual disposable revenue at 2% penetration of the estimated U.S. epidural procedure market, assuming approximately 220,000 annual procedures and a $150 selling price per procedure. This is not a revenue projection and assumes clinical eligibility, physician adoption and disposable purchasing. Approximately $325 per qualifying CPT 0777T procedure has been reported in Novitas and First Coast jurisdictions.
Milestone Scientific (MLSS) outlined physician activity, reimbursement access and commercial coverage for its CompuFlo medical business.
Medical segment revenue has grown, and the Advisor Program collected over 180 epidural procedure feedback submissions through September 2026. Healthcare providers have access to Medicare payment of approximately $325 per CompuFlo-guided procedure under Category III code 0777T in the Novitas and First Coast jurisdictions. The commercial organization includes three dedicated medical sales professionals, approximately 15 sales consultants and three distribution partners.
In a peer-reviewed 79-patient study, CompuFlo-guided epidural access was associated with approximately a 91% reduction in the adjusted odds of composite complications compared with conventional loss-of-resistance techniques. Milestone is expanding activity in Palmetto, pursuing additional payer access and developing markets in Italy, Chile and Qatar.
Milestone Scientific (MLSS) named Pain and Spine Specialists and its Medical Director, Dr. Sudhir Rao, as a CompuFlo development partner and member of the CompuFlo Advisor Program.
Pain and Spine Specialists is a multi-state interventional pain practice with 22 locations across Maryland, Pennsylvania, Virginia and Florida. Its large clinical footprint spans Medicare Jurisdictions L (Novitas Solutions) and N (First Coast Service Options), which the company describes as strategically important for its longer-term reimbursement strategy.
As an advisor and development partner, Dr. Rao and his team will provide real-world feedback on clinical workflows, product functionality, training and future applications of CompuFlo. Milestone Scientific expects the collaboration to support its effort to build clinical experience and supporting evidence as part of its journey toward Category I CPT status for objective epidural confirmation.
Milestone Scientific (NYSE American: MLSS) reported that three board directors converted $465,000 of loans owed by the company into common stock, effective August 19, 2026. The debt-to-equity conversion, priced at $0.50 per share (a 6.4% premium to the August 19 closing price of $0.47), eliminated the company’s outstanding note payable and resulted in a debt-free balance sheet.
The transaction led to the issuance of 976,870 shares of common stock to the participating directors. According to Milestone Scientific, the move strengthens stockholders’ equity and further aligns the interests of these directors with other shareholders.
Milestone Scientific (NYSE: MLSS) reported second quarter 2026 revenue of $2.84 million, up 22% year-over-year, with medical segment revenue rising approximately 231% on strong CompuFlo adoption. Six-month revenue grew 9.8% to $5.0 million.
Q2 gross margin was 67.2% versus 69.6% a year ago, reflecting product mix and higher costs, including tariffs. Operating expenses fell 4.2% to $3.0 million, narrowing the net loss to $1.06 million ($0.01 per share) from $1.48 million. For the first half, operating expenses declined 20.5% and net loss improved to $1.9 million ($0.02 per share).
As of June 30, 2026, cash and cash equivalents were $2.07 million, with working capital of $3.7 million and $466,000 in convertible debt. The company reaffirmed 2026 revenue guidance of $9.8–$10.2 million, expecting double-digit growth and faster expansion in CompuFlo sales.
Milestone Scientific (NYSE: MLSS) will hold a conference call at 8:30 AM Eastern Time on Friday, August 14, 2026, to discuss second quarter 2026 financial results, corporate progress and other developments. Investors can join via toll-free and international phone lines or live webcast, with an audio replay available through August 28, 2026.
Milestone Scientific (NYSE American: MLSS) has entered a strategic distribution agreement with Red One Medical, a federal healthcare distributor serving the U.S. Department of Veterans Affairs (VA), Department of Defense (DoD), Defense Health Agency (DHA), Indian Health Service (IHS) and other federal healthcare organizations. Red One Medical will market, distribute and support Milestone Scientific’s CompuFlo® Epidural System and related disposable products through its federal sales organization and government contracting infrastructure.
The partnership is intended to expand commercial access to CompuFlo across VA medical centers, military treatment facilities and other eligible federal facilities, which together serve more than 18 million enrolled Veterans and military beneficiaries. According to Milestone Scientific, the collaboration may accelerate awareness, product evaluations and commercial opportunities in the federal channel, but the agreement does not guarantee contract awards, evaluations, purchase orders or adoption by any federal agency or facility. CompuFlo is a computer-controlled epidural injection system using Dynamic Pressure Sensing technology and has received 510(k) clearance from the U.S. Food and Drug Administration.
Milestone Scientific (NYSE American: MLSS) launched the first phase of its AI strategy with the pilot debut of Milo, an AI-enabled digital engagement platform, at the American Society of Pain and Neuroscience (ASPN) Annual Conference in Miami Beach, July 16–18, 2026. Milo is designed to complement Milestone’s precision drug delivery and Dynamic Pressure Sensing technologies by delivering intelligent digital engagement, enhanced customer support and scalable commercial operations. Initially, Milo will answer common product questions, provide education, collect customer information, assist with lead qualification and connect healthcare professionals with sales, clinical and support teams.
According to Milestone Scientific, Milo is the first step in a broader AI roadmap built around four initiatives: customer engagement, commercial excellence, clinical innovation and a connected MedTech platform that integrates devices, software, data and AI. The company will use feedback from the ASPN 2026 pilot to direct future Milo and AI development.